PP-151 Prevalence of family dysfunction among patients with chronic liver disease attending communicable disease, research and training center in Suez – Suez Canal University, Suez governorate – Egypt

B.M. Abd El Aziz, M. Salem, M. Mohamed, A. Ahmed
2011 International Journal of Infectious Diseases  
Methods: Works studying the association between polymorphisms of rs12979860 or rs8099917 and the impact on HCV treatment were retrieved in PubMed. After evaluated independently by two researchers, data on the distribution of patients reaching sustained virological response (SVR) in different genotypes of the qualified studies was abstracted and the summary ORs were calculated using the relevant effect model of meta-analysis based on the heterogeneity results in Stata 10.0 software. Results:
more » ... tware. Results: Twenty three studies that met the inclusion criteria were included in the analysis, of which 9 were on rs12979860, 8 on rs8099917 and 6 on both. Comparing to subjects with the rs12979860 CT/TT genotype, HCV infected patients carrying the CC genotype were more likely to reach SVR after the PegIFN-RVB therapy (OR=3.18, 95%CI: 2.33 4.35). A similar result was observed in subjects carrying rs8099917 TT genotype comparing to TG/GG (OR=2.37, 95%CI: 1.73 3.23). As to the subgroup analysis, those positive results above could only be observed in the HCV genotype 1 group, but not in subjects infecting HCV genotype non-1. The publication bias analysis had no statistically significant results. Conclusion: rs12979860 and rs8099917 were involved in the effects of HCV treatment with PegIFN-RVB, but this impact could only be observed in relatively difficult-to-treat genotype 1 subjects. PP-150 Thyroid function in patients with chronic hepatitis-C virus infection under interferon therapy Thyroid dysfunction can be affected as a complication of interferon therapy due to HCV infection. The aims of the present study were to investigate the effect of interferon therapy on the thyroid function on Egyptian patients with HCV infection. The study includes 60 HCV infected patients with normal baseline levels of TSH. The patients receive a subcutaneous pegylated interferon alfa-2b weekly in addition to oral ribavirin (1000 1200 mg/d). The patients were suspected to complete history and clinical examination, with special emphasis to hepatic and thyroid disorders. Before the start of interferon therapy, serum TSH, thyroglobulin-Ab (TG-Ab) and antiperooxidase antibodies (TPO-Ab) were measured. Three months after interferon therapy serum levels of TSH were performed to all patients, patients with abnormal TSH were suspected to the measurements of FT3, FT4, TPO-Ab, TG-Ab and thyroid stimulating immunoglobulin levels (TSI). After 3 months of interferon therapy, 48 patients (80%) had normal TSH and 12 patients (20%) had abnormal TSH. Out of 12 patients had abnormal TSH, 10 patients (16.6%) had high serum levels of TSH (hypothyroidisms), while the remaining 2 patients (3.4%) had low serum levels of TSH (hyperthyroidism). Out of 10 patients with hypothyroidism, 6 patients (10%) had overt hypothyroidism and 4 patients (6.6%) had subclinical hypothyroidism. All patients with abnormal TSH had a significant higher levels of TG-Ab, TPO-Ab and STI. Out of two patients with hyperthyroidism, one patient presented by clinical pictures of overt hyperthyroidism, while the other patient presented by subclinical hyperthyroidism. In conclusion, the incidence of thyroid dysfunction during pegylated interferon therapy in patients with HCV is 20%; hypothyroids was more common than hyperthyroidism. The patients most at risk for thyroid dysfunctions are people with preexisting TPO-Abs. Patients with HCV infection under pegylated interferon and ribavirin therapy should be screened for thyroid dysfunction before and during treatment. Poster Session End Stage Liver Diseases and Complications PP-151 Prevalence of family dysfunction among patients with chronic liver disease attending communicable disease, research and training center in Suez Suez Canal University, Suez governorate Egypt
doi:10.1016/s1201-9712(11)60303-2 fatcat:jrn5hzk2tfarxcejuxoceqyxda